Replies to post #100310 on Biotech Values

[DewDiligence]

Re: SVR12 vs SVR

in clinical practice most if not all physicians are using EOT plus 24 weeks to test for relapse after a successful 48 weeks of Peg + Rib. Perhaps that will change.

For investors, how clinicians define a successful treatment in their individual practices is less consequential than how the FDA and other regulators define it.

I doubt that the FDA and other regulators are in a hurry to replace SVR by SVR12 or any other efficacy metric. For at least the few years and probably longer than that, SVR is what companies are going to have to demonstrate to get their drugs approved.